Table 5.
Results of common variants analysis: a list of the most significantly enriched pathways (P value < 0.05) from gene set enrichment analysis using WebGestalt.
| Accession | Pathway Name | P value | Adjusted P value* |
|---|---|---|---|
| Gene ontology biological process | |||
| GO:0034367 | Macromolecular complex remodeling | 8.12E−03 | 4.61E−01 |
| GO:0048857 | Neural nucleus development | 3.01E−03 | 6.05E−01 |
| GO:0060191 | Regulation of lipase activity | 3.00E−03 | 6.53E−01 |
| GO:0035902 | Response to immobilization stress | 6.15E−03 | 6.79E−01 |
| GO:0002507 | Tolerance induction | 2.97E−02 | 7.11E−01 |
| GO:0090077 | Foam cell differentiation | 1.00E−02 | 8.03E−01 |
| Gene ontology cellular localization | |||
| GO:0032994 | Protein–lipid complex | 9.02E−03 | 4.21E−01 |
| GO:0060076 | Excitatory synapse | 2.53E−02 | 4.80E−01 |
| GO:0098636 | Protein complex involved in cell adhesion | 2.80E−02 | 5.24E−01 |
| GO:1990391 | DNA repair complex | 2.71E−02 | 5.61E−01 |
| GO:0042383 | Sarcolemma | 3.00E−03 | 5.97E−01 |
| GO:0045178 | Basal part of cell | 3.10E−02 | 6.35E−01 |
| Gene ontology molecular function | |||
| GO:0005487 | Nucleocytoplasmic transporter activity | 1.21E−02 | 7.29E−01 |
| KEGG | |||
| hsa04924 | Renin secretion: Homo sapiens (human) | 2.00E−03 | 3.87E−01 |
| hsa04930 | Type II diabetes mellitus: Homo sapiens (human) | 7.00E−03 | 4.13E−01 |
| hsa03430 | Mismatch repair: Homo sapiens (human) | 1.22E−02 | 4.92E−01 |
| PANTHER | |||
| P04378 | Beta2 adrenergic receptor signaling pathway | 4.24E−02 | 2.69E−01 |
| Reactome | |||
| R-HSA-196836 | Vitamin C (ascorbate) metabolism | 1.15E−02 | 4.71E−02 |
| R-HSA-5693616 | Presynaptic phase of homologous DNA pairing and strand exchange | 0.00E+00 | 4.77E−01 |
| R-HSA-170670 | Adenylate cyclase inhibitory pathway | 3.12E−03 | 4.83E−01 |
| R-HSA-71288 | Creatine metabolism | 3.35E−03 | 5.12E−01 |
| R-HSA-997269 | Inhibition of adenylate cyclase pathway | 4.11E−03 | 5.19E−01 |
| R-HSA-3656253 | Defective EXT1 causes exostoses 1, TRPS2 and CHDS | 0.00E+00 | 5.35E−01 |
| R-HSA-448706 | Interleukin-1 processing | 1.84E−02 | 5.41E−01 |
| R-HSA-3656237 | Defective EXT2 causes exostoses 2 | 2.06E−03 | 5.55E−01 |
| R-HSA-8868766 | rRNA processing in the mitochondrion | 2.25E−03 | 5.84E−01 |
| Wikipathways | |||
| WP3407 | FTO Obesity Variant Mechanism | 1.68E−02 | 8.61E−02 |
| WP3601 | Composition of Lipid Particles | 3.39E−03 | 3.44E−01 |
| WP3943 | Robo4 and VEGF Signaling Pathways Crosstalk | 3.40E−02 | 3.65E−01 |
| WP1584 | Type II diabetes mellitus | 7.19E−03 | 4.84E−01 |
| WP3657 | Hematopoietic Stem Cell Gene Regulation by GABP alpha/beta Complex | 1.12E−02 | 5.56E−01 |
| WP3634 | Insulin signaling in human adipocytes (normal condition) | 3.45E−02 | 5.93E−01 |
| WP3635 | Insulin signaling in human adipocytes (diabetic condition) | 2.21E−02 | 6.29E−01 |
| WP2011 | SREBF and miR33 in cholesterol and lipid homeostasis | 1.35E−02 | 6.50E−01 |
| WP3301 | MFAP5-mediated ovarian cancer cell motility and invasiveness | 3.30E−02 | 6.62E−01 |
| WP3844 | PI3K-AKT-mTOR signaling pathway and therapeutic opportunities | 2.51E−02 | 6.62E−01 |
| WP727 | Monoamine Transport | 4.32E−02 | 6.66E−01 |
| WP430 | Statin Pathway | 2.01E−03 | 6.66E−01 |
EXT1 Exostosin 1, TRPS2 Trichorhinophalangeal syndrome type 2, CHDS chondrosarcoma, EXT2 Exostosin 2, Robo4 Roundabout homolog 4, VEGF vascular endothelial growth factor, SREBF Sterol regulatory element-binding transcription factor, MFAP5 Microfibril Associated Protein 5, PI3K Phosphoinositide 3-kinase, AKT Protein kinase B, mTOR mammalian target of rapamycin.
*By Benjamini–Hochberg procedure.
Numbers in bold indicate the smallest adjusted p-values, i.e. most significant pathway enrichments among all rows in the table.